Azasugar-Based MMP/ADAM Inhibitors as Antipsoriatic Agents

Journal of Medicinal Chemistry

Volumn 47, Issue 8, 2004, Pages 1930-1938

  Moriyama, Hideki ^a,b   Tsukida, Takahiro ^a,b,d   Inoue, Yoshimasa ^b   Yokota, Kohichi ^b   Yoshino, Kohichiro ^b   Kondo, Hirosato ^b,d   Miura, Nobuaki ^a   Nishimura, Shin Ichiro ^c  

^a Japan Bioindustry Association   (Japan)

^b Nippon Organon KK   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4' BENZYLOXYBENZENESULFONYL) 3,4,5 TRIHYDROXYPIPERIDINE 2 CARBOXYLIC ACID HYDROXYAMIDE; 1 (4' BUT 2' YNYLOXYBENZENESULFONYL) 3,4,5 TRIHYDROXYPIPERIDINE 2 CARBOXYLIC ACID HYDROXYAMIDE; 3,4,5 TRIHYDROXY 1 (4' METHOXYBENZENESULFONYL)PIPERIDINE 2 CARBOXYLIC ACID HYDROXYAMIDE; 3,4,5 TRIHYDROXY 1 (4' PHENOXYBENZENESULFONYL)PIPERIDINE 2 HYDROXYAMIDE; 3,4,5 TRIHYDROXYPIPERIDINE 2 CARBOXYLIC ACID HYDROXYAMIDE; A DISINTEGRIN AND METALLOPROTEINASE INHIBITOR; ANTIPSORIASIS AGENT; GELATINASE B; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE INHIBITOR; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STABILITY; DRUG SYNTHESIS; EPIDERMIS HYPERPLASIA; HYDROLYSIS; MOUSE; NONHUMAN; TOPICAL TREATMENT;

ADAM PROTEINS; ANIMALS; AZA COMPOUNDS; CARBOHYDRATES; DISEASE MODELS, ANIMAL; DISINTEGRINS; EPIDERMAL GROWTH FACTOR; HYDROXAMIC ACIDS; HYPERPLASIA; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; METALLOENDOPEPTIDASES; MICE; MODELS, MOLECULAR; PROTEASE INHIBITORS; PSORIASIS; SKIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 1842555113     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0304313     Document Type: Article

References (32)

1. Thacher, S. M.; Vasudevan, J.; Tsang, K.-Y.; Nagpal, S.; Chandraratna, R. A. S. New Dermatological Agents for the Treatment of Psoriasis. J. Med. Chem. 2001, 44, 1.
2. Ashcroft, D. M.; Po, A. L. W.; Griffiths, C. E. M. Thrapeutic strategy for psoriasis. J. Clin. Pharm. Ther. 2000, 25, 1.
3. Shoyab, M.; Plowman, G. D.; McDonald, V. L.; Bradley, J. G.; Todaro, G. J. Structure and function of human amphiregulin: a member of the epidermal growth factor family. Science 1989, 243, 1074.
4. (a) Higashiyama, S.; Abraham, J. A.; Miller, J.; Fiddes, J. C.; Klagsbrun, M. A. heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991, 251, 936.
5. (b) Raab, G.; Klagsburn, M. Heparin-binding EGF-like growth factor. Biochim. Biophys. Acta 1997, 1333, F179-F199.
6. Cook, P. W.; Piepkorn, M.; Clegg, C. H.; Plowman, G. D.; DeMay, J. M.; Brown, J. R.; Pittekknow, M. R. Transgenic Expression of the Human Amphregulin Gene Induces a Psoriasis-like Phenotype. J. Clin. Invest. 1997, 100, 2886.
7. Stoll, S.; Garner, W.; Elder, J. Heparin-binding Ligands Mediate Autocrine Epidermal Growth Factor Receptor Activation In Skin Organ Culture. J. Clin. Invest. 1997, 100, 1271.
8. Piepkorn, M.; Pittekknow, M. R.; Cook, P. W. Autocrine Regulation of Keratinocytes: The Emerging Role of Heparin-Binding, Epidermal Growth Factor-Related Growth Factors. J. Invest. Dermatol. 1998, 111, 715.
9. Tokumaru, S.; Higashiyama, S.; Endo, T.; Nakagawa, T.; Miyanaga, J.; Yamamori, K.; Hanakawa, Y.; Ohmoto, H.; Yoshino, K.; Shirakata, Y.; Matsuzawa, Y.; Hashimoto, K.; Taniguti, N. Ectodomain Shedding of Epidermal Growth Factor Receptor Ligands Is Required for Keratinocyte Migration in Cutaneous Wound Healing. J. Cell. Biol. 2000, 151, 209.
10. Arribas, J.; Borroto, A. Protein Ectodomain Shedding. Chem. Rev. 2002, 102, 4627.
11. Prenzel, N.; Zwick, E.; Daub, H.; Leserer, M.; Abraham, R.; Wallasch, C. ; Ullrich, A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999, 402, 884.
12. Asakura, M.; Kitakaze, M.; Takashima, S.; Liano, Y.; Ishikura, F.; Yoshinaka, T.; Ohmoto, H.; Node, K.; Yoshino, K.; Ishiguro, H.; Asanuma, H.; Sanada, S.; Matsumura, Y.; Takeda, H.; Beppu, S.; Tada, M.; Hori, M.; Higashiyama, S. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy. Nature Med. 2002, 8, 35.
13. Lanzrein, M.; Grarred, O.; Olsnes, S.; Sandvig, K. Diphtheria toxin endocytosis and membrane translocation are dependent on the intact membrane-anchored receptor (HB-EGF receptor): studies on the cell-associated receptor cleaved by a metalloproteinase in phorbol-ester-treated cells. Biochem. J. 1995, 310, 285.
14. (a) Sawa, M.; Tsukamoto, T.; Kiyoi, T.; Kurokawa, K.; Nakajima, F.; Nakada, Y.; Yokota, K.; Inoue, Y.; Kondo, H.; Yoshino, K. New Strategy for Antedrug Application: Development of Metalloproteinase Inhibitors as Antipsoriatic Drugs. J. Med. Chem. 2002, 45, 930.
15. (b) Yoshiizumi, K.; Yamamoto, M.; Miyasaka, T.; Ito, Y.; Kumihara, H.; Sawa, M.; Kiyoi, T.; Yamamoto, T.; Nakajima, F.; Hirayama, R.; Kondo, H.; Ishibushi, E.; Ohmoto, H.; Inoue, Y.; Yoshino, K. Synthesis and Structure-Activity Relationships of 5,6,7,8-Tetrahydropyrido[3,4-b]pyrazine-based Hydroxamic Acids as HB-EGF Shedding Inhibitors. Bioorg. Med. Chem. 2003, 11, 433.
16. (a) Zook, S. E.; Dagnino, R. Jr.; Deason, M. E.; Bender, S. L.; Melnick, M. J. Metalloproteinase Inhibitors, Pharmaceutical Compositions Containing Them and Their Pharmaceutical Uses, and Methods and Intermediates Useful For Their Preparation. PCT Int. Appl. WO9720824, 1997.
17. (b) Cheng, M.; De, B.; Pikul, S.; Almsread, N. G.; Natchus, M. G.; Anastasio, M. V.; McPhail, S. J.; Snider, C. E.; Twaio, Y. O.; Chen, L.; Dunaway, M.; Gu, F.; Dowty, M. E.; Mieling, C. E.; Mieling, G. E.; Janusz, M. J.; Wang-Weigand, S. Design and Synthesis of Piperazine-Based Matrix Metalloproteinase Inhibitors. J. Med. Chem. 1999, 42, 2, A.
18. (c) Almstead, N. G.; Bradley, R. S.; Pikul, S.; De, B.; Natchus, M. G.; Taiwo, Y. O.; Gu, F.; Williams, L. E.; Hynd, B. A.; Janusz, M. J.; Dunaway, C. M.; Mieling, G. E. Design, Synthesis, and Biological Evaluation of Potent Thiazine- and Thiazepine-Based Matrix Metalloproteinase Inhibitors. J. Med. Chem. 1999, 42, 4547.
19. (d) Whittaker, M.; Floyd, C. D.; Brown, P. Gearing, A. J. T. Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors. Chem. Rev. 1999, 99, 2735.
20. (a) Moriyama, H.; Tsukida, T.; Inoue, Y.; Kondo, H.; Yoshino, K.; Nishimura, S.-I. Structure-Activity Relationships of Azasugar Based MMP/ADAM Inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 2737.
21. (b) Moriyama, H.; Tsukida, T.; Inoue, Y.; Kondo, H.; Yoshino, K.; Nishimura, S.-I. Design, Synthesis and Evaluation of Novel Azasugar-Based MMP/ADAM Inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 2741.
22. Compound 2 bearing methoxy group was also stable in pH 7.4 solution and distilled water after 1 week.
23. (a) Csuka, R.; Hugener, M.; Vassela, A. A New Synthesis of N-Acetylneuraminic Acid. Helv. Chim. Acta 1988, 71, 609.
24. (b) Lee, B. W.; Jeong, I.-Y.; Yang, M. S.; Choi, S. U.; Park, K. H. A Short and Efficient Synthesis of 2R,3R,4R-3,4-Dihydroxyproline, 1,4-Dideoxy-1,4-imino-L-xylitol, 2R,3R,4R-3,4,5-Trihydroxypipecolic Acid, and 1,5-Dideoxy-1,5-imino-L-iditol. Synthesis 2000, 1305.
25. D-Mannono-1,4-lactone is commercial available from Tokyo Kasei Kogyo Co., Ltd.
26. Xiao, X.; Bai, D. An Efficient and Selective Method for Hydrolysis for Acetonide. Synlett 2001, 535.
27. (a) Yamamoto, M.; Tsujishita, H.; Hori, N.; Ohishi, Y.; Inoue, S.; Ikeda, S.; Okada, Y. Inhibition of Membrane-Type 1 Matrix Metalloproteinase by Hydroxamate Inhibitors: An Examination of Subsite Pocket. J. Med. Chem. 1998, 41, 1209.
28. (b) Lovejoy, B.; Welch, A. R.; Carr, S.; Luong, C.; Broka, C.; Hendricks, R. T.; Campell, J. A.; Walker, K. A. M.; Martin, R.; Van Wart, H.; Browner, M. F. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat. Struct. Biol. 1999, 6, 217.
29. (a) Davidson, A. N.; Backer, R. C. Novel use of Matrix Metalloproteinase Inhibitors. PCT Int. Appl. WO9847494, 1998.
30. (b) Holleran, W. M.; Galardy, R. E.; Gao, W. N.; Levy, D.; Tang, P. C.; Elias, P. M. Matrix Metalloproteinase Inhibitors reduce phorbol ester-induced cutaneous inflammation and hyperplasia. Arch. Dermatol. Res. 1997, 289, 138.
31. Nagase, H.; Fields, C. G.; Fields, G. B. Design and Characterization of a Fluorogenic Substrate Selectively Hydrolyzed by Stromelysin 1 (Matrix Metalloproteinase-3). J. Biol. Chem. 1994, 269(33), 20952.
32. Van Dyk, D. E.; Marchand, P.; Bruckner, R. C.; Fox, J. W.; Jaffee, B. D. ; Gunyuzlu, P. L.; Davis, G. L.; Nurnberg, S.; Convington, M.; Decicco, C. P.; Trzaskos, J. M.; Magolda, R. L.; Copeland, R. A. Comparison of Snake Venom Reprolysin and Matrix Metalloproteinases as Models of TNF-α Converting Enzyme. Bioorg. Med. Chem. Lett. 1997, 7(10), 1219.